SA
DNA icon

Strategic Advocates’s Ginkgo Bioworks DNA Stock Holding History

Strategic Advocates’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.5K Buy
7,267
+2,886
+66% +$24K 0.2% 82
2025
Q4 		$35.7K Buy
4,381
+3,899
+809% +$42K 0.01% 228
2025
Q3 		$7.03K Buy
+482
New +$5.77K ﹤0.01% 381

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Advocates's DNA Position: Q1 2026 in Review

Strategic Advocates increased its Ginkgo Bioworks (DNA) stake by 66% in Q1 2026, buying an estimated $24K and bringing the position to 7,267 shares worth $44.5K. The position accounts for 0.2% of the portfolio, ranked #82.

Strategic Advocates first reported a position in DNA in Q3 2025 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Strategic Advocates held 7,267 shares of Ginkgo Bioworks worth $44.5K as of Q1 2026.
  • Strategic Advocates bought 2,886 Ginkgo Bioworks shares in Q1 2026, an estimated $24K.
  • Ginkgo Bioworks made up 0.2% of Strategic Advocates's portfolio in Q1 2026, its #82 holding.
  • Strategic Advocates first reported a position in Ginkgo Bioworks in Q3 2025 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.